Arrakis Therapeutics

Ribometrix

The company develops small molecule therapeutics targeting RNA structures to treat human diseases for pharmaceutical partners and patients with cancer or neurodegenerative conditions.

ArQule

This biopharmaceutical company develops targeted small molecule drug candidates to treat cancers and rare diseases for patients with unmet medical needs.

Arvinas

This biopharmaceutical company develops protein degradation therapies to treat patients with cancer and neurodegenerative diseases.

ADARx Pharmaceuticals

This clinical-stage biotechnology company develops RNA-targeting therapeutics for patients with genetic, cardiometabolic, complement-mediated, and central nervous system diseases.

Aptadir Therapeutics

The company develops RNA inhibitor-based therapeutics that reactivate silenced genes to treat patients with intractable cancers and rare genetic conditions.

Ribonaut Therapeutics

Ribonaut Therapeutics develops small molecule drugs that target and degrade disease-causing RNA to treat neurological conditions and movement disorders for human patients.

Atavistik Bio

This biotechnology company develops oral allosteric small molecule therapeutics for patients with rare hematological diseases and cancers.

Typewriter Therapeutics

The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.